Benicar Lawsuit Lawyer – Settlements, Recalls & Help - Stomach Issues
IVC Filter Lawsuit Header IVC Filter Lawsuit Header

This website covers the details of the Benicar litigation, including the connection to sprue-like enteropathy, and the $300 million nationwide settlement announced in August 2017.

You must have been represented by an attorney by August 23, 2017, to be eligible to participate in the $300 million settlement.

 

Important Benicar Settlement Information

In August 2017, a $300 million settlement was reached with Daiichi Sankyo on behalf of individulals who filed lawsuits after suffering sprue-like enteropathy and other gastrointestinal issues from Benicar, Benicar HCT, Azor and Tribenzor. Our law firm was one of the lead negotiators of this settlement.

 

Why Were Benicar Lawsuits Being Filed

Thousands of claims were filed against Daiichi Sankyo (the manufacturer of Benicar) by people who suffered sprue-like enteropathy and other gastrointestinal issues as a result of taking Benicar.

In August 2017 a $300 million settlement was reached for individuals who suffered gastrointestinal issues after taking Benicar.

Attorneys argued that if doctors and patients had known the risks, they would have used a blood pressure medication other than Benicar, or would have been closely monitored for symptoms similar to celiac disease.

Read More
 

What are the Allegations in the Benicar Litigation

  1. Benicar is defective and unreasonably dangerous;
  2. Daiichi Sankyo was negligent in the manufacturing of Benicar;
  3. Daiichi Sankyo failed to properly test Benicar, and failed to warn doctors and patients of the potential for sprue-like enteropathy and other gastrointestinal problems; and
  4. Daiichi Sankyo concealed evidence of the dangers of Benicar from the government and the public, and misrepresented the safety of the drug in its marketing material.

 

What is the Purpose of Benicar

Benicar (marketed as Benicar, Benicar HCT, Azor and Tribenzor) is a blood pressure medication that blocks certain receptors, known as angiotensin receptors. Angiotensin II is a hormone that causes the blood vessels to constrict.

By inhibiting the action of this hormone (as well as reducing the secretion and production of other hormones involved in regulating blood pressure), blood vessels become dilated.

Read More
 

Drugs of this class generate approximately $7 billion in revenue for the manufacturers. There are a number of angiotensin receptor blockers (ARBs) on the market, but only Benicar has been implicated in the development of the intestinal disorder known as sprue-like enteropathy.

Often misdiagnosed as celiac disease, sprue-like enteropathy prevents the intestinal system from properly absorbing nutrients from food. In essence, a patient who is not treated for this condition literally starves to death.

 

Benicar Injuries & Side Effects

Benicar Side Effects

A study conducted at the Mayo Clinic by Dr. Josephy Murray linked the development of sprue-like enteropathy to the use of Benicar. Sprue-like enteropathy is a disease that produces severe gastrointestinal symptoms; such as chronic diarrhea, significant weight loss, nausea, and overall malnutrition.

The most serious side effects are symptoms that appear to be Celiac disease, but actually are sprue-like enteropathy.

Dr. Murray conducted the study on 22 patients who were using Benicar and experiencing gastrointestinal symptoms, initially diagnosed as Celiac disease. However, the patients in the study were not responding to a gluten-free diet, a common form of treatment for Celiac disease, and did not have detectable tissue transglutaminase in their blood, which is used to positively diagnose celiac disease.

Upon discontinuation of Benicar, all 22 patients experienced relief from the gastrointestinal symptoms as well as weight gain. Dr. Murray concluded that the Benicar being taken by the patients was directly linked to the gastrointestinal symptoms the patients were experiencing. Dr. Murray’s study and findings on the link between Benicar use and sprue-like enteropathy was recently published online in the Mayo Clinic Proceedings, and began the process of Benicar lawyers filing Benicar Lawsuits.

Read More
Celiac Disease Issues

Celiac Disease and Sprue-like Enteropathy: Many patients that are taking Benicar have been diagnosed wrongfully with Celiac Disease. The injury caused by Benicar (‘Sprue-like Enteropathy’) mimics Celiac Disease. Benicar attacks the villi in the small intestine for patients that are susceptible to this reaction, just as patients who have Celiac will have their villi atrophied or flattened after ingesting gluten.

Patients that are taking Benicar may have had a biopsy taken during an endoscopy and this biopsy showed villous atrophy or villous blunting. Because villous atrophy is a common finding to show that patients have Celiac Disease, their gastroenterologists will often diagnose their patients with Celiac Disease. However, many patients have found that they do not have Celiac Disease, but rather, they had ‘Sprue-like Enteropathy’ caused by Benicar.

These patients found this out because a gluten-free diet did not alleviate their symptoms at all. Rather, these patients’ symptoms were only alleviated after discontinuing Benicar. Some patients were diagnosed with Celiac Disease at the same time that they stopped taking Benicar. After years of being on a gluten-free diet, they realized after specifically discussing their Benicar usage with their gastroenterologist that the Benicar may have been the culprit of their villous atrophy (and their GI symptoms).

If you ingested Benicar and were diagnosed with Celiac Disease for the first time while ingesting Benicar, you should consider speaking to a gastroenterologist about this.

 
Benicar Heart Issues

Heart Issues: Two large clinical studies have also shown an unexpectedly high risk of cardiovascular death in diabetic patients associated with the use of Benicar. Similarly, a study published in the European Heart Journal revealed that Benicar combined with β-blockers and ACE inhibitors increase the risk of myocardial infarction (heart attacks) and strokes.

 

Benicar Lawsuit Videos

 
Watch More Videos
 

Benicar Lawsuit News

Benicar News Banner
Daiichi's Benicar Pact Brings Payout Over Drugs to $339 Million

"Daiichi officials agreed Monday to pay $300 million to resolve patient suits over its Benicar, Benicar HCT, Azor and Tribenzor blood-pressure treatments. The accord comes more than two years after the Chuo-Ku, Japan-based company paid $39 million to resolve the U.S. government’s allegations that it paid illegal kickbacks to doctors who prescribed the medicines." Reported in Bloomberg - Benicar $339 Million Payout

FDA Adds GI Warning to Benicar Label

"The FDA ordered the maker of the blood pressure drug olmesartan (Benicar) to add a warning about the risk of an intestinal condition known as sprue-like enteropathy to the drug's label." Reported in MedPage - FDA Gastrointestinal Warning

For additional news stories, click Levin Law Benicar News

 

FDA and Scientific Studies Regarding Benicar

Benicar FDA Research Banner

The FDA has approved label changes to Benicar to list the link to sprue-like enteropathy

The U.S. Food and Drug Administration (FDA) is warning that the blood pressure drug olmesartan medoxomil (marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics) can cause intestinal problems known as sprue-like enteropathy. Reported in FDA Benicar Safety Communication

Severe Spruelike Enteropathy Associated With Olmesartan

Benicar may be associated with a severe form of spruelike enteropathy. Clinical response and histologic recovery are expected after suspension of the drug. Reported in Mayo Clinic - Invokana Spruelike Enteropathy

Olmesartan (Benicar) and Drug-Induced Enteropathy

"An association between olmesartan [Benicar] and sprue-like enteropathy has been observed in several case series and reports. Patients 57 to 81 years of age, irrespective of gender, have experienced weight loss of up to 40 kg while taking this drug. Although the mechanism precipitating this adverse effect remains uncertain, it is essential to consider olmesartan-associated enteropathy in patients with biopsy-proven villous atrophy when no other cause can be found." Reported in Pharmacy and Therapeutics - Drug-Induced Enteropathy